hotspot -WSS

hotspot

author：entertainment 2025-09-28 20:32:58 - browse：19742

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Liquid biopsy for lung cancer is launched by Delfi

Wikipedia

WSS

RaDonda Vaught to speak at CommonSpirit event on patient safety

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA does about

The future of health care in the House

The future of health care in the House

Chemotherapy drug shortage eases slightly but still widespread

focus

hotspot

Wikipedia

Psychedelics group wrestles with new pharma identity

Chan Zuckerberg Biohub Chicago to focus on inflammation

Duchenne breakthrough therapy leaves behind pioneering families

Histogen: Failed biotech offers rare public look inside

Sports medicine is finally prioritizing gender equality

Bill would stop addiction treatment from triggering child abuse inquiry

In Memoriam: Notable people who died in 2023

FDA authorizes Novavax’s updated Covid

The cancer drug shortage isn’t new — and neither are the solutions

Why getting cancer drugs just got harder for rural patients

hotspot

Bill would stop addiction treatment from triggering child abuse inquiry

Change Healthcare cyberattack outage could last weeks

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Chan Zuckerberg Biohub Chicago to focus on inflammation

Clinical trials giant ICON acquires HumanFirst

Flu vaccine offering decent levels of protection this winter, new data show

leisure time

Wikipedia

knowledge

explore